ZyVersa Therapeutics Inc 2026年季度报告

FORM 10-Q (Mark One) For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________to_________ Commission File Number: 001-41184 ZYVERSA THERAPEUTICS, INC.(Exact name of registrant as specified in its charter) Delaware86-2685744(State or other jurisdictionof incorporation or organization)(I.R.S. EmployerIdentification No.) 2436 N. Federal Highway, Suite 466Lighthouse Point, FL 3306433064(Address of principal executive offices)(Zip Code) (754) 231-1688(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Common Stock, $0.0001 par value per share ZVSA Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. Yes:☒No:☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes:☒No:☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer Accelerated filerSmaller reporting companyEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark if the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes:☐No:☒ The Company’s common stock is quoted on the OTCQB® Venture Market under the symbol “ZVSA.” As of May 11, 2026, the number of shares outstanding of the registrant’s common stock, $0.0001 par value per share, was 8,095,921. ZYVERSA THERAPEUTICS, INC.INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS PART I - FINANCIAL INFORMATION1Item 1. Financial Statements.1Condensed Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 20251Unaudited Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 20252Unaudited Condensed Consolidated Statements of Changes in Stockholders’ (Deficit) Equity for the Three MonthsEnded March 31, 2026 and 20253Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20254Notes to Unaudited Condensed Consolidated Financial Statements5ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.14ITEM 3. Quantitative and Qualitative Disclosures About Market Risk.21ITEM 4. Controls and Procedures.21PART II - OTHER INFORMATION22ITEM 1. Legal Proceedings.22ITEM 1A. Risk Factors.22ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.22ITEM 3. Defaults Upon Senior Securities.22ITEM 4. Mine Safety Disclosures.22ITEM 5. Other Information.22ITEM 6. Exhibits.22SIGNATURES23 ZYVERSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS ZYVERSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) The accompanying notes are an integral part of these condensed consolidated financial statements. ZYVERSA THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Note 1 – Business Organization, Nature of Operations and Basis of Presentation Organization and Operations ZyVersa Therapeutics, Inc. (“ZyVersa” and the “Company”) is a clinical stage biopharmaceutical company leveraging proprietarytechnologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs.The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accountingprinciples generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they donot include all of the information and disclosures required by accounting principles generally accepted in the United States of Americafor annual financial s